Mapi Hits Milestone For Viatris-Partnered Long-Acting Glatiramer
More Than 600 Patients Now Dosed In Pivotal Phase III Trial
Executive Summary
Fresh from a $20m investment from partner Viatris, Mapi Pharma has announced significant progress in its Phase III trial for a long-acting version of Copaxone, which is to be filed through the FDA’s 505(b)(2) hybrid pathway.
You may also be interested in...
Viatris Sues Teva In US Over ‘Illegal Copaxone Scheme’
Viatris’ Mylan has accused Teva of creating a perfect ‘playbook’ to delay Mylan’s launch of a generic version of its Copaxone blockbuster and then strangle uptake, something Mylan was vocal about years earlier, in a suit filed in a New Jersey court.
Mylan and Mapi ally on glatiramer acetate
Mylan is teaming up with Israeli firm Mapi Pharma to develop and commercialise a long-acting glatiramer acetate product, Mapi’s ‘GA Depot’ candidate. Subject to approval from the Israeli Innovation Authority, the partnership sees Mylan acquire global marketing rights for the once-monthly injection for treating relapsingremitting multiple sclerosis (RRMS).
US Supreme Court Reignites Claims Government Overcharged Millions For Generics
In a case that could have significant ramifications for the scope of the US False Claims Act, the US Supreme Court has agreed to remand for further proceedings allegations that supermarket and pharmacy chains defrauded the government via low-cost drug programs.